Can Parkinson's disease lead to dementia and are there combined trials?

Yes, Parkinson's disease dementia (PDD) affects up to 50% of Parkinson's patients. Some trials specifically target PDD or dementia with Lewy bodies, which overlaps with both conditions. However, most trials are disease-specific — Alzheimer's trials typically exclude Parkinson's patients and vice versa.

Are the new Alzheimer's drugs available in clinical trials?

Yes. Anti-amyloid therapies like lecanemab and donanemab are available in UK clinical trials. These represent a major breakthrough in Alzheimer's treatment. Additionally, anti-tau therapies and other novel approaches are in active trials. Parkinson's trials focus on dopamine therapies, gene therapy, and neuroprotective agents.

What biomarker testing is needed for neurodegenerative disease trials?

For Alzheimer's: amyloid PET scan or CSF biomarkers (amyloid beta, p-tau) are typically required. Blood-based biomarkers are increasingly accepted. APOE4 genotyping may be needed for some trials. For Parkinson's: DaTscan, LRRK2/GBA genetic testing, and alpha-synuclein detection are common requirements.

Neurology Comparison Updated 26 May 2026

Alzheimer's vs Parkinson's Disease — Clinical Trial Comparison

🧠

Alzheimer's Disease

Progressive memory and cognitive decline

🧠

Parkinson's Disease

Progressive motor and movement disorder

Alzheimer's Disease and Parkinson's Disease are the two most common neurodegenerative conditions in the UK. Both involve progressive protein aggregation in the brain, but they affect different brain regions and produce different symptoms. Their clinical trial landscapes are evolving rapidly with breakthrough treatments.

Key Differences at a Glance

Feature	Alzheimer's Disease	Parkinson's Disease
Primary protein	Amyloid beta plaques + tau tangles	Alpha-synuclein (Lewy bodies)
Brain region affected	Cerebral cortex, hippocampus	Substantia nigra (dopamine neurons)
Primary symptoms	Memory loss, cognitive decline, behavioural changes	Tremor, rigidity, bradykinesia, postural instability
Key biomarkers	Amyloid beta, p-tau, APOE4, NfL	LRRK2, GBA, SNCA, alpha-synuclein
Diagnostic test	Amyloid PET, CSF analysis, blood biomarkers	DaTscan, clinical examination
Dementia overlap	Core feature	~50% develop PDD (Parkinson's Disease Dementia)

Clinical Trial Availability

Trial Aspect	Alzheimer's Disease	Parkinson's Disease
UK trials actively recruiting	40–70 studies	25–50 studies
Most common trial phase	Phase 2–3	Phase 2–3
Breakthrough treatments	Anti-amyloid (lecanemab, donanemab)	Gene therapy, deep brain stimulation advances
Prevention trials	Active (APOE4 carriers, MCI patients)	Emerging (LRRK2/GBA carriers)
Biomarker-driven trials	Rapidly growing (amyloid-positive required)	Growing (genetic subtypes)
Device trials	Neurostimulation	Deep brain stimulation (major category)

Treatment Approaches in Current Trials

Alzheimer's Disease — Hot Trial Areas

Anti-amyloid antibodies — lecanemab, donanemab (approved in UK, ongoing trials)
Anti-tau therapies — targeting neurofibrillary tangles
Amyloid vaccine — active immunisation approaches
Anti-inflammatory approaches — targeting neuroinflammation
Lifestyle interventions — diet, exercise, cognitive training
Neurostimulation — TMS, tDCS for cognitive symptoms

Parkinson's Disease — Hot Trial Areas

Gene therapy — AAV-delivered GAD, AADC, GBA gene replacement
Anti-alpha-synuclein — prasinezumab, cinpanemab
LRRK2 kinase inhibitors — for LRRK2-mutant Parkinson's
GBA-targeted therapies — ambroxol, venglustat for GBA-mutant
Neuroprotective agents — slowing disease progression
Advanced DBS — adaptive/closed-loop deep brain stimulation

💡 A new era for neurodegenerative trials

2024-2026 has seen a paradigm shift in neurodegenerative disease trials. For Alzheimer's, the first disease-modifying treatments (anti-amyloid antibodies) are now available, and trials are expanding into earlier detection and prevention. For Parkinson's, gene therapy trials and alpha-synuclein targeting represent genuine breakthroughs after decades of limited progress.

Eligibility Differences

Alzheimer's Trial Criteria

Amyloid-positive status required for most modern trials (PET scan or CSF/blood test)
Disease stage classification: preclinical, MCI, mild dementia, moderate
MMSE or CDR-SB scores define severity thresholds
APOE4 genotype affects some trial eligibility (higher ARIA risk with anti-amyloid therapy)
Brain MRI required to exclude other causes and assess baseline
Study partner/caregiver required for most trials

Parkinson's Trial Criteria

Clinically confirmed Parkinson's diagnosis (UK Brain Bank criteria)
Disease stage (Hoehn & Yahr scale) determines trial category
Motor fluctuation status (wearing off, dyskinesia) for advanced therapy trials
Dopaminergic medication requirements vary
Genetic testing (LRRK2, GBA) for genotype-specific trials
Cognitive screening — many motor trials exclude significant dementia

🧠 Alzheimer's Disease Trials

Find actively recruiting Alzheimer's clinical trials across the UK

View Alzheimer's Trials

🧠 Parkinson's Disease Trials

Find actively recruiting Parkinson's clinical trials across the UK

View Parkinson's Trials

Concerned about memory or movement symptoms?

Early diagnosis opens more trial options. Speak with your GP about referral to a neurologist or memory clinic. Many trials now target the earliest stages of disease.

Open Smart Matcher